SynthesisFrontiers in oncology2025
Predictors and oncological outcomes of achieving Pentafecta in radical cystectomy: a meta-analysis.
Synthesis in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aims to evaluate the predictive value of RC-Pentafecta on overall survival (OS) and cancer-specific survival (CSS) after radical cystectomy (RC) through meta-analysis and to explore the perioperative predictors of RC-Pentafecta. Method: This systematic review and meta-analysis were conducted in accordance with the PRISMA statement. We systematically searched PubMed, Embase, Cochrane Library, and Web of Science databases and included 9 retrospective studies from 2020 to 2025. The fixed effect model and random effect model were used for combined analysis. Results: The results of the study showed that patients who achieved RC-Pentafecta had significantly better OS and CSS than those who did not. In addition, Age, length of hospital stay (LOS), American Association of Medical Sciences Anesthesiology (ASA) score, diabetes mellitus, hypertension, Type of Urinary diversion (UD), pathological T-stage (pT), and pathological N-stage (pN) showed significant differences among the groups that achieved RC-Pentafecta. Conclusions: RC-Pentafecta is a valuable criterion that can effectively predict OS and CSS in patients after RC. Age, perioperative health status, and pathological stage are important predictors of RC-Pentafecta.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.